Next Article in Journal
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer
Next Article in Special Issue
Emerging Cancer Vaccines: The Promise of Genetic Vectors
Previous Article in Journal
Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer
Previous Article in Special Issue
Novel Antibody-Based Proteins for Cancer Immunotherapy
Cancers 2011, 3(3), 3461-3495; doi:10.3390/cancers3033461

New Approaches to Immunotherapy for HPV Associated Cancers

* ,
The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Qld 4102, Australia
* Authors to whom correspondence should be addressed.
Received: 1 August 2011 / Revised: 26 August 2011 / Accepted: 29 August 2011 / Published: 2 September 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [379 KB, uploaded 2 September 2011]   |  


Cervical cancer is the second most common cancer of women worldwide and is the first cancer shown to be entirely induced by a virus, the human papillomavirus (HPV, major oncogenic genotypes HPV-16 and -18). Two recently developed prophylactic cervical cancer vaccines, using virus-like particles (VLP) technology, have the potential to prevent a large proportion of cervical cancer associated with HPV infection and to ensure long-term protection. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and do not prevent their progression to HPV-associated malignancy. In animal models, therapeutic vaccines for persisting HPV infection can eliminate transplantable tumors expressing HPV antigens, but are of limited efficacy in inducing rejection of skin grafts expressing the same antigens. In humans, clinical trials have reported successful immunotherapy of HPV lesions, providing hope and further interest. This review discusses possible new approaches to immunotherapy for HPV associated cancer, based on recent advances in our knowledge of the immunobiology of HPV infection, of epithelial immunology and of immunoregulation, with a brief overview on previous and current HPV vaccine clinical trials.
Keywords: HPV; vaccine; virus-like particles; immunotherapy HPV; vaccine; virus-like particles; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Bergot, A.-S.; Kassianos, A.; Frazer, I.H.; Mittal, D. New Approaches to Immunotherapy for HPV Associated Cancers. Cancers 2011, 3, 3461-3495.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert